1

FDA Attacks Brain Health Supplements

We think this is to pave the way for a new blockbuster drug. Action Alert! In October we told you about a potential new blockbuster drug for Alzheimer’s from drug giant Eli Lilly. Solanezumab is in the third and final phase of FDA drug trials, and if approved, could bring in at least $7.6 billion in sales by 2024 and probably much more. …